https://go.evvnt.com/965900-0?pid=5248 Online Event
Boston, Massachusetts 02108
$Industry Pricing - Conference + Focus Day USD 2798.00, Industry Pricing - Conference Only USD 2099.00
Lectures & Conferences
The 3rd STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field.
With multiple TLR agonists moving into the clinic, STING agonists exposing new challenges, multiple approvals on the horizon, and more novel targets & combinations currently undergoing exciting pre-clinical validation than ever before, this unique and highly anticipated industry-focused meeting will unite experts in innate immunity to overcome the barriers it faces and accelerate clinical breakthrough.
Returning in-person to the biopharma hub of Boston, 30+ expert speakers will take you through case-study led presentations, juicy panel discussions and live Q&A’s, all tailored to suit your TLR, STING & other PRR targeting needs.
Gain connections and insights to plan how to optimize the development of your innate immune agonists into the clinic and overcome obstacles that may impede the delivery of more selective, better-tolerated medicines to improve survival rates in difficult-to-treat cancers.
Speakers: Michael J. Newman Founder & Chief Scientific Officer Indaptus Therapeutics, Kate Fitzgerald Professor - Program in Innate Immunity, Division of Infectious Diseases & Immunology UMass Medical School, Robert Andtbacka Chief Medical Officer Seven and Eight Biopharmaceuticals, Shannon Morris Vice President of Clinical Development Istari Oncology, Babette Schade Head of Biology Lab & Principal Scientist TargImmune Therapeutics, Diwakar Davar Assistant Professor - Phase, Therapeutics & Melanoma University of Pittsburgh, Mingchao Kang Group Lead, Head Technology Platform Ambrx, Joshi Ramanjulu Senior Director & Head of Project Leader Group, Innate Immunity Research Unit & Senior Fellow GlaxoSmithKline, John Flygare Senior Principal Scientist Merck & Co, Roxana Schillaci Senior Researcher Instituto de Biología y Medicina Experimental, Buenos Aires (IBYME), Adi Diab Associate Professor - Melanoma Medical Oncology MD Anderson Cancer Center, Arthur Krieg Chief Executive Officer Checkmate Pharmaceuticals, Sonia Maciá Director - Medical Highlight Therapeutics, Jim Appleman Chief Scientific Officer, CoFounder, Director & Senior Vice President - Research & Development Primmune Therapeutics, Matt Booty Lead Scientist Spring Discovery, Brian Horsburgh Chief Executive Officer Activate Therapeutics, Lei Jin Assistant Professor - Medicine University of Florida, Bettina Werle Chief Scientific Officer Tollys, Tracy Kuo Senior Director - Biology & Translational Science Tallac Therapeutics, Peter DeMuth Vice President - Research Elicio Therapeutics, Stuart Hughes Chief Executive Officer Pathios Therapeutics, Juho Jalkanen Chief Development Officer Faron Pharmaceuticals, Karim Kasmi Senior Principal Scientist Boehringer Ingelheim, Swaminathan P. Iyer Professor of Medicine, Department of Lymphoma/Myeloma MD Anderson Cancer Center, Austin Bigley Vice President & Director of Research & Development Indapta Therapeutics, Timo K. van den Berg Senior Director ImmunoOncology Byondis, Elsa Sanchez-Lopez Assistant Professor Department of Orthopaedic Surgery School of Medicine University of California San Diego, Kamal Puri Chief Scientific Officer Oncoresponse, Jasper Mullenders Director Translation Biology Scenic Biotech, Andrew Miller Co-founder & Vice President - Immunology & Operations Apros Therapeutics